Use of Continuous Glucose Monitoring in Pump Therapy Sensor Augmented Pump or Automated Insulin Delivery in Different Age Groups (0.5 to <26 Years) With Type 1 Diabetes From 2018 to 2021: Analysis of the German/Austrian/Swiss/Luxemburg Diabetes Prospective Follow-up Database Registry.

Autor:	van den Boom L; Division of Pediatrics/Pediatric Diabetology, DRK Hospital, Kirchen, Germany.; Division of Pediatric Diabetology, Endocrinology, Metabolism and Obesity, Children's Hospital, University of Bonn, Bonn, Germany., Auzanneau M; Institute of Epidemiology and Medical Biometry, Central Institute for Biomedical Technology, University of Ulm, Ulm, Germany.; German Center for Diabetes Research, Neuherberg, Germany., Woelfle J; Children's and Adolescent's Hospital, University of Erlangen, Erlangen, Germany., Sindichakis M; Department of Pediatrics, Kliniken Südostbayern, Traunstein, Germany., Herbst A; Centre for Paediatrics, Medical Clinic Leverkusen, Leverkusen, Germany., Meraner D; Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria., Hake K; Children's Hospital, Müritzklinikum Waren, Waren, Germany., Klinkert C; Pediatric Practice, Herford, Germany., Gohlke B; Division of Pediatric Diabetology, Endocrinology, Metabolism and Obesity, Children's Hospital, University of Bonn, Bonn, Germany., Holl RW; Institute of Epidemiology and Medical Biometry, Central Institute for Biomedical Technology, University of Ulm, Ulm, Germany.; German Center for Diabetes Research, Neuherberg, Germany.
Jazyk:	angličtina
Zdroj:	Journal of diabetes science and technology [J Diabetes Sci Technol] 2024 Sep; Vol. 18 (5), pp. 1122-1131. Date of Electronic Publication: 2023 Feb 25.
DOI:	10.1177/19322968231156601
Abstrakt:	Aim: Insulin pump, continuous glucose monitoring (CGM), and sensor augmented pump (SAP) technology have evolved continuously leading to the development of automated insulin delivery (AID) systems. Evaluation of the use of diabetes technologies in people with T1D from January 2018 to December 2021. Methods: A patient registry (Diabetes Prospective Follow-up Database [DPV]) was analyzed for use of SAP (insulin pump + CGM ≥90 days, no automated dose adjustment) and AID (HCL or LGS/PLGS). In total 46,043 people with T1D aged 0.5 to <26 years treated in 416 diabetes centers (Germany, Austria, Luxemburg, and Switzerland) were included and stratified into 4 groups A-D according to age. Additionally, TiR and HbA1c were analyzed. Results: From 2018 to 2021, there was a significant increase from 28.7% to 32.9% (sensor augmented pump [SAP]) and 3.5% to 16.6% (AID) across all age groups, with the most frequent use in group A (<7 years, 38.8%-40.2% and 10.3%-28.5%). A similar increase in SAP and AID use was observed in groups B (7 to <11 years) and C (11 to <16 years): B: +15.8 PP, C: +15.9 PP. HbA1c improved significantly in groups C and D (16 to <26 years) (both P < .01). Time in range (TiR) increased in all groups (A: +3 PP; B: +5 PP; C: +5 PP; D: +5 PP; P < 0.01 for each group). Insulin pumps (61.0% versus 53.4% male) and SAP (33.5% versus 28.9% male) are used more frequently in females. Conclusion: In recent years, we found an increasing use of new diabetes technologies and an improvement in metabolic control (TiR) across all age groups. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: LvdB received honoraria for lectures from Medtronic, Insulet and Eli Lilly. The other authors have no disclosures.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu